세계의 제약 및 바이오테크놀러지 인공지능(AI) 시장

Global Artificial Intelligence (AI) in Pharma and Biotech Market to Reach US$9.0 Billion by 2030

The global market for Artificial Intelligence (AI) in Pharma and Biotech estimated at US$3.1 Billion in the year 2024, is expected to reach US$9.0 Billion by 2030, growing at a CAGR of 19.2% over the analysis period 2024-2030. Drug Discovery & Development Application, one of the segments analyzed in the report, is expected to record a 17.9% CAGR and reach US$2.6 Billion by the end of the analysis period. Growth in the Clinical Trials & Optimization Application segment is estimated at 17.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$822.8 Million While China is Forecast to Grow at 18.3% CAGR

The Artificial Intelligence (AI) in Pharma and Biotech market in the U.S. is estimated at US$822.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 18.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 17.5% and 16.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.3% CAGR.

Global Artificial Intelligence (AI) in Pharma and Biotech Market - Key Trends & Drivers Summarized

How Is AI Revolutionizing the Drug Discovery and Development Lifecycle?

Artificial Intelligence is dramatically reshaping the pharmaceutical and biotechnology industries by accelerating and optimizing the entire drug discovery and development process. Traditional drug development is an expensive, time-consuming endeavor that often takes over a decade and costs billions of dollars to bring a single new drug to market. AI is changing this paradigm by enabling the rapid analysis of massive datasets, such as genomics, proteomics, and clinical trial records, to identify viable drug targets and predict the behavior of chemical compounds. Machine learning algorithms can sift through thousands of potential molecules and rank them based on predicted efficacy, toxicity, and bioavailability, thereby streamlining the preclinical screening phase. Generative AI models are even capable of designing novel molecular structures that meet specified therapeutic requirements. Moreover, AI is improving the selection and validation of biomarkers, helping researchers match drugs to the right patient populations more effectively. These innovations not only speed up early-stage R&D but also reduce the risk of failure in costly late-stage trials. Natural language processing tools are being used to analyze scientific literature, patents, and clinical databases to uncover previously overlooked insights. By integrating real-world evidence and historical data, AI enhances predictive modeling, supports hypothesis generation, and allows for more informed go/no-go decisions during development. The net result is a more agile and data-driven drug discovery model, reducing time to market and improving the chances of clinical success. AI’s role in drug development is no longer experimental; it is becoming an essential tool for pharmaceutical innovation, helping companies bring new treatments to patients faster and more efficiently.

What Role Is AI Playing in Clinical Trials, Personalized Medicine, and Regulatory Compliance?

AI is making a profound impact on clinical trial management, personalized medicine, and regulatory workflows, areas that are traditionally laden with complexity, variability, and inefficiency. In clinical trials, AI is being deployed to optimize patient recruitment, one of the biggest bottlenecks in trial execution. By analyzing electronic health records, genetic data, and social determinants of health, AI systems can identify eligible patients faster and predict their likelihood of adherence and response to treatment. AI also supports adaptive trial designs, where protocols are modified in real-time based on incoming data, improving trial efficiency and statistical power. For personalized medicine, AI is crucial in deciphering the biological uniqueness of individual patients and matching them with targeted therapies. Algorithms analyze genomic sequences, protein expressions, and even microbiome profiles to predict drug response and minimize adverse effects, paving the way for more customized treatment plans. In regulatory affairs, AI helps ensure compliance by automating the monitoring of guideline updates, safety alerts, and labeling requirements across different markets. Intelligent document processing tools are being used to prepare submissions, identify inconsistencies, and streamline interactions with regulatory agencies such as the FDA and EMA. Pharmacovigilance is another area benefiting from AI, where machine learning systems are used to detect adverse event signals from disparate data sources, including social media, clinical notes, and post-marketing reports. These capabilities reduce manual workload and enhance the accuracy and timeliness of safety assessments. By transforming the clinical, personalized, and regulatory landscape, AI is not only accelerating the path from lab to patient but also ensuring that treatments are safer, more effective, and more tailored to individual needs.

How Are Pharma and Biotech Companies Integrating AI into Their Business Models and R&D Infrastructure?

Pharma and biotech companies are increasingly embedding AI into their core business strategies and R&D infrastructure to stay competitive in an innovation-driven landscape. Large pharmaceutical firms are forming strategic partnerships with AI startups and tech companies to co-develop platforms for target identification, compound screening, and trial optimization. These collaborations enable access to specialized expertise and proprietary datasets that can significantly accelerate R&D timelines. Many companies are also establishing internal AI centers of excellence, hiring data scientists, bioinformaticians, and computational chemists to integrate AI capabilities across departments. Cloud-based platforms and high-performance computing are being adopted to handle the massive volume of data generated from genomics, clinical studies, and digital health applications. AI-driven platforms are being used for portfolio prioritization, helping decision-makers assess which assets to advance or shelve based on predictive analytics. On the manufacturing side, AI supports process optimization, quality control, and predictive maintenance, ensuring consistent product quality and reducing operational costs. In sales and marketing, AI tools analyze market trends, prescription patterns, and customer feedback to develop personalized engagement strategies for healthcare providers and patients. Additionally, AI is playing a growing role in digital therapeutics and companion diagnostics, enabling the development of integrated treatment solutions that combine traditional drugs with software-driven monitoring and behavioral interventions. This shift toward AI-centric business models is not limited to large enterprises. Emerging biotech firms are using AI from day one to differentiate themselves, build leaner operations, and attract investment. As AI matures, it is becoming a strategic enabler that cuts across every phase of the pharmaceutical value chain, fostering a culture of innovation, speed, and precision.

What Is Driving the Sustained Global Growth of AI in the Pharma and Biotech Market?

The growth in the artificial intelligence in pharma and biotech market is driven by a combination of rising healthcare demands, expanding datasets, technological innovation, and a favorable regulatory and investment environment. The global burden of chronic and complex diseases such as cancer, Alzheimer’s, and rare genetic disorders is creating an urgent need for faster and more effective therapeutic solutions. AI helps meet this need by accelerating drug discovery and improving treatment precision. The widespread adoption of electronic health records, genomic sequencing, and wearable health devices has created a vast and growing pool of structured and unstructured data that fuels AI models. Technological advancements in natural language processing, machine learning, and neural networks have made it possible to analyze this data in ways that were previously unimaginable, unlocking insights that guide drug development, clinical decision-making, and market access strategies. Government initiatives and public-private partnerships aimed at fostering AI innovation in life sciences are also supporting growth, providing funding and policy support for research and deployment. Venture capital investment in AI-focused biotech startups continues to surge, reflecting strong confidence in the market potential of AI-driven drug development. The emergence of precision medicine and the push for patient-centric healthcare are further reinforcing the demand for AI tools that enable personalized treatment strategies. Global pharmaceutical companies are also under pressure to reduce costs and improve R&D efficiency, making AI a compelling solution for sustaining innovation. As more success stories emerge, such as AI-discovered drug candidates entering clinical trials, the credibility and adoption of AI in the life sciences continue to grow. These factors are collectively fueling a robust and sustained expansion of the AI market within the pharma and biotech sectors, signaling a new era of data-driven, technology-enabled healthcare innovation.

SCOPE OF STUDY:

The report analyzes the Artificial Intelligence (AI) in Pharma and Biotech market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application, Other Applications); End-User (Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

• AbbVie
• AstraZeneca
• Biogen
• Boehringer Ingelheim
• CureMetrix
• Exscientia
• Flatiron Health
• GSK
• IBM Watson Health
• Insilico Medicine
• Johnson & Johnson
• Lilly
• Medtronic
• Merck & Co.
• NVIDIA
• PathAI
• Recursion Pharmaceuticals
• Sanofi
• Tempus
• Zymergen

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Artificial Intelligence (AI) in Pharma and Biotech - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising R&D Costs and Long Development Cycles Spur Demand for AI-Driven Drug Discovery and Optimization Platforms
  • Here's How Generative AI Strengthens the Business Case for De Novo Molecule Design and Target Prediction
  • Integration of AI with Omics and Real-World Data Throws the Spotlight on Precision Medicine and Biomarker Discovery
  • Here's the Story: Natural Language Processing Enables Deep Mining of Scientific Literature and Biomedical Databases
  • AI-Powered Predictive Modeling Enhances Compound Screening, Toxicity Assessment, and Lead Candidate Prioritization
  • Digital Twins and Simulation Technologies Expand the Addressable Market for In Silico Testing and Virtual Clinical Trials
  • AI in Bioprocess Optimization and Manufacturing Improves Yield, Scalability, and Quality Control in Biotech Operations
  • Growing Focus on Rare Diseases and Orphan Drug Development Supports Use of AI to Identify Small, High-Impact Patient Populations
  • Here's the Story: Regulatory Acceptance of AI in Drug Development Workflows Drives Frameworks for Validation and Compliance
  • Integration of AI in Pharmacovigilance Enhances Post-Marketing Surveillance and Signal Detection Capabilities
  • Expansion of AI-Powered Platforms in Vaccine Development Demonstrates Potential in Rapid Response to Emerging Pathogens
  • Here's How Cloud Infrastructure and Data Interoperability Accelerate the Scalability of AI Tools Across the Drug Development Lifecycle
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Artificial Intelligence (AI) in Pharma and Biotech Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Drug Discovery & Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for Drug Discovery & Development Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Clinical Trials & Optimization Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for Clinical Trials & Optimization Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Predictive Maintenance & Quality Control Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World 6-Year Perspective for Predictive Maintenance & Quality Control Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Drug Target Identification Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 11: World 6-Year Perspective for Drug Target Identification Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Disease Diagnosis & Prognosis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 13: World 6-Year Perspective for Disease Diagnosis & Prognosis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 17: World 6-Year Perspective for Pharma & Biotech Companies End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 18: World Recent Past, Current & Future Analysis for Academic & Contract Research Organizations End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 19: World 6-Year Perspective for Academic & Contract Research Organizations End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World 6-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 22: USA Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 23: USA 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
  • TABLE 24: USA Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 25: USA 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
• CANADA
  • TABLE 26: Canada Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: Canada 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
  • TABLE 28: Canada Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 29: Canada 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
• JAPAN
  • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 30: Japan Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 31: Japan 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
  • TABLE 32: Japan Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Japan 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
• CHINA
  • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 34: China Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 35: China 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
  • TABLE 36: China Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 37: China 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
• EUROPE
  • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 38: Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: Europe 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 40: Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 41: Europe 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
  • TABLE 42: Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 43: Europe 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
• FRANCE
  • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 44: France Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: France 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
  • TABLE 46: France Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 47: France 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
• GERMANY
  • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 48: Germany Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 49: Germany 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
  • TABLE 50: Germany Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Germany 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
• ITALY
  • TABLE 52: Italy Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 53: Italy 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
  • TABLE 54: Italy Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 55: Italy 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
• UNITED KINGDOM
  • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 56: UK Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: UK 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
  • TABLE 58: UK Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 59: UK 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 60: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 61: Rest of Europe 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
  • TABLE 62: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Rest of Europe 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
• ASIA-PACIFIC
  • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 64: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 65: Asia-Pacific 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
  • TABLE 66: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 67: Asia-Pacific 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
• REST OF WORLD
  • TABLE 68: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Rest of World 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
  • TABLE 70: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 71: Rest of World 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030

IV. COMPETITION